22nd Century Group, Inc.
8201 Main Street
116 articles with 22nd Century Group, Inc.
22nd Century Files 2019 First Quarter Report and Announces Conference Call to Provide Business Update
22nd Century’s proposed VLN™ cigarettes continue to fall squarely within the nicotine range that public health officials anticipate will be mandated by the FDA.
Mr. Pritchard was formerly the Head of Regulatory Science for Imperial Brands, U.K.
22nd Century Announces Exclusive Worldwide Agreement with KeyGene for Genetic Development of Hemp/Cannabis
Strategic collaboration will bolster 22nd Century’s position as a global leader in hemp/cannabis genetics.
22nd Century has had more than 20 conversations with the FDA on matters relating to the Company’s PMT and MRTP applications
22nd Century’s New Study Confirms Very Low Nicotine Content Cigarettes Result in 97% Less Nicotine in Smoker’s Bloodstream
The results indicate that subjects using the VLNC product had 97% less nicotine in their blood as compared to their blood-nicotine levels after use of their usual brand of highly addictive commercial cigarettes.
The FDA has accepted for review the Company’s MRTPA for VLNTM cigarettes
Kaplan Fox & Kilsheimer LLP is investigating claims on behalf of investors of 22nd Century Group, Inc.
President Trump Signs Bill Legalizing Low-THC Cannabis
A PMTA is an important first step toward achieving potentially the first – and only – Modified Risk Tobacco Product marketing order for a combustible cigarette
22nd Century Group, Inc. today commented on a highly deceptive article published yesterday by a self-professed short seller of the Company’s stock who launched his smear campaign in an effort to dupe shareholders into selling their shares of 22nd Century Group stock.
22nd Century Group, Inc. (NYSE American: XXII), a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that on October 11, 2018, Dr. Lynn Hull, Lead Pharmacologist at the Food and Drug Administration (FDA) Center for Tobacco Products, held a webcast highlighting and summarizing the published science supporting the FDA’s efforts to dramatically reduce nicotine in all cigarettes sold in the United States.
JAMA Publishes Greatly Anticipated Phase III Study Using 22nd Century’s SPECTRUM® Very Low Nicotine Content Cigarettes
Immediate reduction in nicotine content is the clear winner.
Very Low Nicotine Content will eliminate all cigarettes’ ability to create and sustain addiction.
Company significantly increases spending and strategic initiatives in support of MRTP application and FDA’s ANPRM for reduced nicotine cigarettes.
Nondaily Smokers Who Switch to 22nd Century’s Very Low Nicotine Content Cigarettes Reduce their Consumption by a Staggering 51%
Intermittent smokers assigned to VLNC cigarettes reduced both the overall number of cigarettes smoked and the number of days on which they smoked
Reynolds American and Phillip Morris unable to comply with the FDA’s plan “for 20-year
Scientists highlight reduced consumption; refute claims of compensation; support an immediate reduction in nicotine level
22nd Century Group, Inc. called attention to comments submitted to the U.S. Food and Drug Administration (FDA) in response to the FDA’s Advance Notice of Proposed Rulemaking (ANPRM) to develop a nicotine product standard in cigarettes that will lower nicotine to minimally or non-addictive levels.
22nd Century Group, Inc. announced that the Company will be added to the Russell 2000, Russell 3000, and Russell Global Indexes when FTSE Russell (Russell) reconstitutes its U.S. and global equity indexes on June 22, 2018.
22nd Century Group, Inc. announced that the Company will present at the Citi 2018 Small & Mid Cap Conference.